Keywords: inegy, outperforms, lipitor, hdl/ldl, diabetes, study, usa-based
Inegy outperforms Lipitor in HDL/LDL diabetes study
Article | 09 April 2007
USA-based drug major Merck & Co says that its dual-action cholesterol-lowerer Inegy (combined ezetimibe/simvastatin) was shown to be more effective ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
